- Total: 362 patients
- 189 patients were men
- 259 patients were older than 60
- 115 patients received ACEIs/ARBs
- 77 patients died in the hospital 


University of Michigan - Ann Arbor

Smith College

In a retrospective analysis, researchers investigated whether patients with hypertension who received ACEIs/ARBs experienced heightened complications of the illness or were at a greater risk of mortality during COVID-19 infection. 


Studying the effect of ACE inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs) in COVID-19 Patients with Hypertension (Wuhan, China)

Li, J., Wang, X., Chen, J., Zhang, H., & Deng, A. (2020). Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA cardiology.

doi:10.1001/jamacardio.2020.1624

https://jamanetwork.com/journals/jamacardiology/article-abstract/2765049

Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China

- The different drug treatments show no difference in the progression of the infection and risk of fatality during hospitalization for COVID-19 patients with hypertension 
- Results suggest that COVID-19 patients with hypertension should not discontinue taking ACEIs, ARBs, or other antihypertensive drugs because of infection 
- Patients with hypertension became more sick from COVID-19 infection and had higher mortality rates than COVID-19 patients without hypertension


Discussion of Studying the effect of ACE inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs) in COVID-19 Patients with Hypertension (Wuhan, China)

- Patients taking ACEIs/ARBs had a higher prevalence of coronary artery disease 
- Patients not taking ACEIs/ARBs had higher alkaline phosphate levels
- For the most part, all patients had similar comorbidities and laboratory profile results, such as blood cell counts, inflammatory markers, renal and liver function tests, and cardiac biomarkers
- ACEI/ARB treatment and calcium channel blockers did not affect the frequency of severity of illness, acute respiratory distress syndrome, and mortality among the hypertension patients  


Results of Studying the effect of ACE inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs) in COVID-19 Patients with Hypertension (Wuhan, China)

Learn Before

Related